2-(溴甲基)-3-氯吡啶 | 1227515-76-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-(溴甲基)-3-氯吡啶
• 英文名称: 2-(Bromomethyl)-3-chloropyridine
• CAS: 1227515-76-5
• 化学式: C₆H₅BrClN
• 分子量: 206.469
• InChiKey: SRDFDJYHNRNJOL-UHFFFAOYSA-N

物化性质

• 沸点：
  226.5±25.0 °C(Predicted)
• 密度：
  1.663±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-(溴甲基)-3-氯吡啶 在 水 、 sodium 、 sodium hydride 、 氯乙酸 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙醇 为溶剂， 生成 5-[(3-chloropyridin-2-yl)methyl]-6-(4-phenylcyclohexyl)-1H-pyrimidine-2,4-dione
  参考文献：
  名称：

  Discovery of a novel non-steroidal GR antagonist with in vivo efficacy in the olanzapine-induced weight gain model in the rat

  摘要：

  We report the optimization of a series of non-steroidal GR antagonists that led to the identification of compound 7. This compound is efficacious when dosed orally in an olanzapine-induced weight gain model in rats. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.10.074

文献信息

• [EN] BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF GLYTL MEDIATED DISORDERS<br/>[FR] DÉRIVÉS DE BENZOXAZINONE POUR TRAITER DES TROUBLES INDUITS PAR GLYTL
  申请人：GLAXO GROUP LTD

  公开号：WO2011012622A1

  公开（公告）日：2011-02-03

  The present invention relates to benzoxazinone derivatives, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in treating disorders mediated by GlyT1, including neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder.

  本发明涉及苯并噁唑酮衍生物，其制备方法，含有它们的药物组合物和药物，以及它们在治疗由GlyT1介导的疾病中的应用，包括神经系统和神经精神疾病，特别是精神病、痴呆或注意力缺陷障碍。
• [EN] PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS<br/>[FR] DÉRIVÉS DE LA PURINE EN TANT QU'AGONISTES DU RÉCEPTEUR CB2
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014177490A1

  公开（公告）日：2014-11-06

  The invention relates to a compound of formula (I) wherein A and R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

  该发明涉及一种化合物，其化学式为(I)，其中A和R1至R4的定义如描述和权利要求中所述。化合物的化学式(I)可用作药物。
• 2,4-DIAMINOPYRIMIDINE DERIVATIVES AS HISTAMINE H4 MODULATORS
  申请人：Janssen Pharmaceutica NV

  公开号：US20180289706A1

  公开（公告）日：2018-10-11

  The present invention relates to 2,4-diaminopyrimidines and pharmaceutically acceptable salts thereof, purification methods for the same, pharmaceutical compositions containing them, methods of obtaining and using them for the treatment of disease states, disorders, and conditions mediated by the histamine H 4 receptor activity.

  本发明涉及2,4-二氨基嘧啶及其药用盐，其纯化方法，含有它们的药物组合物，以及用于治疗由组胺H4受体活性介导的疾病状态、紊乱和病况的获取和使用方法。
• Novel tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists
  申请人：Wyeth

  公开号：US20030018026A1

  公开（公告）日：2003-01-23

  This invention provides novel substituted tricyclic carboxamides which act as oxytocin receptor competitive antagonists, as well as methods of their manufacture, pharmaceutical compositions and methods of their use in treatment, inhibition, suppression or prevention of preterm labor, dysmenorrhea and endometritis, suppression of labor at term prior to caesarean delivery, and to facilitate antinatal transport to a medical facility. These compounds are also useful in enhancing fertility rates, enhancing survival rates and synchronizing estrus in farm animals; and may be useful in the prevention and treatment of disfunctions of the oxytocin system in the central nervous system including obsessive compulsive disorder (OCD) and neuropsychiatric disorders.

  该发明提供了新颖的替代三环羧酰胺，其作为催产素受体竞争性拮抗剂，以及其制备方法、药物组合物和在治疗、抑制、压制或预防早产、痛经和子宫内膜炎、在剖宫产前抑制分娩以及促进孕妇转运至医疗机构的使用方法。这些化合物还可用于提高农场动物的生育率、提高存活率和同步动物的发情期；并且可能在预防和治疗中枢神经系统中催产素系统功能障碍，包括强迫症（OCD）和神经精神障碍方面具有用处。
• PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS
  申请人：Hoffmann-La Roche Inc.

  公开号：US20160046631A1

  公开（公告）日：2016-02-18

  The invention relates to a compound of formula (I) wherein A and R 1 to R 4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

  本发明涉及一种式（I）的化合物，其中A和R1到R4的定义如说明书和权利要求所述。该式（I）的化合物可用作药物。